C4 Therapeutics Q2 EPS $(0.73) Misses $(0.69) Estimate, Sales $2.66M Miss $6.44M Estimate; Cash, Cash Equivalents And Marketable Securities Of $286.7M Will Be Sufficient To Fund Planned Operating Expenses And Capital Expenditures Into 2H Of 2025
Portfolio Pulse from Benzinga Newsdesk
C4 Therapeutics reported Q2 losses of $(0.73) per share, missing the analyst consensus estimate of $(0.69) by 5.8%. The company's quarterly sales were $2.66M, missing the estimate of $6.44M by 58.63%. However, the company's cash, cash equivalents and marketable securities of $286.7M will be sufficient to fund planned operating expenses and capital expenditures into the second half of 2025.
August 08, 2023 | 11:22 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
C4 Therapeutics reported a larger than expected loss and lower than expected sales for Q2. However, the company has sufficient cash reserves to fund operations into 2H 2025.
The company's larger than expected loss and lower than expected sales could negatively impact the stock price in the short term. However, the company's strong cash position could provide some reassurance to investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100